Home > Focus Areas > Type 2 Diabetes Connect > Post
4yr
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493717/
Atherosclerotic cardiovascular disease (ASCVD) refers to a condition that involves cholesterol buildup in the arteries, often presenting as coronary heart disease, cerebrovascular disease, and peripheral artery disease of atherosclerotic origin. ASCVD is the leading cause of morbidity and mortality among individuals with diabetes globally, resulting in an estimated annual cost of $37.3 billion [ 1].
• Source: Cardiovascular Diabetology
• Conclusion/Relevance: “This study showed that AIP [atherogenic index of plasma] might be a strong biomarker that could be used to predict the risk of cardiovascular events in patients with T2DM.”
• The current secondary analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study included 10,251 patients with long-lasting T2DM. The researchers assessed the relationship between AIP and major adverse cardiovascular events (MACEs), including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes, as well as secondary outcomes (all-cause mortality).
• AIP refers to a logarithmically transformed ratio of triglyceride (TG) to high-density lipoprotein-cholesterol (HDL-C) in molar concentration, and is a sensitive marker of lipoprotein profiles. It could predict the size of lipoprotein particles and be positively correlated with CVD risk. Additionally, AIP can inform the severity of insulin resistance. AIP was also been found to be a novel independent prognostic biomarker of coronary artery disease and arterial stiffness, in addition to traditional risk factors.
• “In this retrospective analysis of T2DM patients with high CVD risk, AIP was a parameter related to abnormal lipid and glucose metabolism. The occurrence of MACEs of the high AIP group was significantly higher than that of the low AIP group,” wrote the authors. “These differences were mainly caused by cardiovascular death and non-fatal myocardial infarction. In the subgroup analysis, we found that AIP has a consistent effect on the prognosis of T2DM patients. Therefore, AIP can be used as a predictor of the long-term prognosis of patients with T2DM.”
• This study had certain limitations. First, it was a post hoc analysis with the possibility of confounding variables at play. Second, the study population was mostly White, with results possibly not generalizable to other populations. Third, calculation parameters for AIP were not obtained during the study, and changes were not recorded during follow-up.